AI Article Synopsis
Article Abstract
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer's disease (AD) in 64 countries.
Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm(2) (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm(2) (18-mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch in Japanese patients with AD.
Results: In the primary analysis population (intent-to-treat last observation carried forward) at week 24, delayed deterioration was seen with the 10-cm(2) patch versus placebo on the Japanese version of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-J cog; p = 0.005) and the Japanese version of the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC plus-J; p = 0.067). Participants receiving the rivastigmine patch showed numerically less decline versus placebo at week 24 on the CIBIC plus-J, although this did not reach statistical significance. Statistical significance for the CIBIC plus-J was met following adjustment for body weight and baseline Mini-Mental State Examination score as dynamic allocation factors (p = 0.042) and on the Disability Assessment for Dementia (DAD; p = 0.024) and Mental Function Impairment (MENFIS; p = 0.016) subscales. Serious adverse events were rare and were consistent with the known safety profile of the rivastigmine patch.
Conclusion: The rivastigmine patch has a favorable efficacy and tolerability profile in Japanese patients with AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199883 | PMC |
| http://dx.doi.org/10.1159/000328929 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease.
J Alzheimers Dis
December 2024
Brain Health Unit (CIMES), School of Medicine, University of Málaga, IBIMA, Málaga, Spain.
Background: Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge.
Objective: To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD.
Implantable trilayer microneedle transdermal delivery system to enhance bioavailability and brain delivery of rivastigmine for Alzheimer treatment: A proof-of-concept study.
Eur J Pharm Biopharm
August 2024
Faculty of Pharmacy, Hasanuddin University, Makassar 90245, South Sulawesi, Indonesia. Electronic address:
Alzheimer's disease (ALZ) is a neurological disorder characterized by cognitive decline. Rivastigmine (RV), an acetylcholinesterase inhibitor, is commonly used to treat ALZ. Unfortunately, RV is availablein capsule form, which is associated with low drug bioavailability, and in patch form, which can lead to skin irritation upon repeated use.
View Article and Find Full Text PDFThe donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.
Expert Rev Neurother
June 2024
Department of Psychiatry and Behavioral Neurology, Division of Geriatric Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USA.
Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.
Areas Covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials.
Rivastigmine for the management of anticholinergic delirium.
Clin Toxicol (Phila)
February 2024
Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.
Introduction: Anticholinergic agents are commonly taken in overdose, often causing delirium. The spectrum of anticholinergic delirium ranges from mild agitation to severe behavioural disturbance. Physostigmine is an effective treatment for anticholinergic delirium, but its availability is limited.
View Article and Find Full Text PDFGuidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
J Neurosci Rural Pract
October 2023
Centre for Brain Research, Indian Institute of Science, Bengaluru, Karnataka, India.
Article Synopsis
- The rise in dementia, particularly Alzheimer’s disease (AD), necessitates a deeper understanding of its causes and treatments to enhance patient and caregiver quality of life.
- AD’s pathophysiology involves the buildup of amyloid-beta plaques and tau protein abnormalities, leading to neurotransmitter imbalances that affect brain function.
- FDA-approved treatments for AD can be divided into those addressing behavioral symptoms (like brexpiprazole for agitation) and cognitive decline (such as donepezil, a commonly prescribed cholinesterase inhibitor), each with specific mechanisms and side effects that require monitoring.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!